Analysts Are Downgrading These 5 Pharmaceutical Stocks

4. Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI)

Number of Hedge Fund Holders: 3

Checkmate Pharmaceuticals Inc (NASDAQ:CMPI) is developing a new approach to cancer immunotherapy. It’s focusing on CpG oligonucleotides to discover and develop immunotherapies designed to increase the efficacy of existing immunotherapies.

BTIG analyst Kaveri Pohlman recently downgraded Checkmate Pharmaceuticals (NASDAQ:CMPI) to Neutral from Buy without a price target after the company agreed to be acquired by Regeneron (REGN) for $10.50 per share in cash.